Ascendis Pharma A/S

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies using its proprietary TransCon technology platform, which enables sustained-release prodrug formulations designed to improve efficacy, safety, and patient convenience. The company markets three commercial products: YORVIPATH (palopegteriparatide) for hypoparathyroidism in adults, SKYTROFA (lonapegsomatropin) as a once-weekly growth hormone therapy for pediatric growth hormone deficiency, and YUVIWEL (navepegritide) for achondroplasia in children. Ascendis operates across the U.S. and more than 35 international markets, with an expanding pipeline targeting rare endocrine diseases and new therapeutic areas including combination therapy for pediatric achondroplasia and investigations in hypochondroplasia. The company trades on Nasdaq under the ticker ASND and reports financial results in euros under IFRS. Updated Aug 13, 2026